secnidazole · Evofem Inc · NDA 209363
Solosec
Earliest generic entry, as listed
11 Dec 2041
Blocked by patent: US 12280037. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 33 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12280037 | use U-3302 | 11 Dec 2041 |
| US 11684607 | product, use U-3270 | 16 Sep 2035 |
| US 11684607 | product, use U-3169 | 16 Sep 2035 |
| US 11684607 | product, use U-2583 | 16 Sep 2035 |
| US 11684607 | product, use U-3302 | 16 Sep 2035 |
| US 10335390 | product, use U-2583 | 4 Sep 2035 |
| US 10335390 | product, use U-3270 | 4 Sep 2035 |
| US 10682338 | product, use U-2583 | 4 Sep 2035 |
| US 10682338 | product, use U-3270 | 4 Sep 2035 |
| US 10849884 | product, use U-3169 | 4 Sep 2035 |
| US 10849884 | product, use U-2583 | 4 Sep 2035 |
| US 10849884 | product, use U-3270 | 4 Sep 2035 |
| US 10849884 | product, use U-3302 | 4 Sep 2035 |
| US 10857133 | product, use U-3270 | 4 Sep 2035 |
| US 10857133 | product, use U-2583 | 4 Sep 2035 |
| US 11000507 | product, use U-3169 | 4 Sep 2035 |
| US 11000507 | product, use U-3302 | 4 Sep 2035 |
| US 11000507 | product, use U-3270 | 4 Sep 2035 |
| US 11000507 | product, use U-2583 | 4 Sep 2035 |
| US 11000508 | product, use U-3169 | 4 Sep 2035 |
| US 11000508 | product, use U-2583 | 4 Sep 2035 |
| US 11000508 | product, use U-3270 | 4 Sep 2035 |
| US 11000508 | product, use U-3302 | 4 Sep 2035 |
| US 11020377 | product, use U-3270 | 4 Sep 2035 |
| US 11020377 | product, use U-3302 | 4 Sep 2035 |
| US 11020377 | product, use U-2583 | 4 Sep 2035 |
| US 11020377 | product, use U-3169 | 4 Sep 2035 |
| US 11324721 | product, use U-3169 | 4 Sep 2035 |
| US 11324721 | product, use U-3270 | 4 Sep 2035 |
| US 11324721 | product, use U-2583 | 4 Sep 2035 |
| US 11324721 | product, use U-3302 | 4 Sep 2035 |
| US 11602522 | product, use U-3169 | 4 Sep 2035 |
| US 11602522 | product, use U-3302 | 4 Sep 2035 |
Exclusivities · 1 unexpired
| GAIN | qualified infectious disease product | 15 Sep 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209363 · 001 · RLD | granule, oral | 2GM/PACKET | 11 Dec 2041 |
Expired or delisted (1)
- NCE · 15 Sep 2022